Lowering luspatercept dose for lower-risk myelodysplastic anemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether gradually lowering the dose of luspatercept can help people with lower-risk myelodysplastic syndromes (MDS) who have anemia. It may help reduce side effects while still improving blood counts or symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have MDS that is “lower-risk” with an IPSS-R score of 3.5 or less
- Your hemoglobin is below 100 g/L (at the start of the study)
- You tried an ESA/EPO (like epoetin) before but didn’t respond or couldn’t tolerate it (or your EPO level was 500 U/L or higher)
- Your overall health/function is good enough (ECOG 0 to 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This trial tests whether luspatercept can help improve low red blood cell counts (anemia) that happens soon after a stem cell transplant. It is for people with blood cancers who have very low hemoglobin after transplant.
Hear when a new Lower Risk MDS Per IPSS-R trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.